Abstract: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.
Type:
Grant
Filed:
September 7, 2010
Date of Patent:
June 4, 2013
Assignee:
Affimed Therapeutics, AG
Inventors:
Claudia Linhard, Stefan Knackmuss, Melvyn Little, Karlheinz Peter, Peter Roettgen, Meike Schwarz
Abstract: Described are mono- and multivalent scFv-antibodies comprising the binding sites specific for the human T cell marker CD3. These antibodies are strongly immunosuppressive and do not cause a significant release of cytokines. Furthermore, polynucleotides encoding said antibodies are described as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Pharmaceutical compositions containing any of the above mentioned polynucleotides, antibodies or vectors are useful for immunotherapy, preferably against acute transplant rejections.
Abstract: Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.
Type:
Grant
Filed:
April 5, 2006
Date of Patent:
March 8, 2011
Assignee:
Affimed Therapeutics AG
Inventors:
Melvyn Little, Stefan Knackmuss, Uwe Reusch, Sergey Kipriyanov, Fabrice Le Gall, Vera Mick, Karin Hoffmann, Peter Röttgen
Abstract: The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.
Type:
Grant
Filed:
October 4, 2002
Date of Patent:
October 12, 2010
Assignee:
Affimed Therapeutics, AG
Inventors:
Claudia Buettner, Stefan Knackmuss, Melvyn Little, Karlheinz Peter, Peter Roettgen, Meike Schwarz
Abstract: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.
Type:
Grant
Filed:
October 8, 2004
Date of Patent:
March 24, 2009
Assignee:
Affimed Therapeutics AG
Inventors:
Stefan Knackmuss, Clémence Rey, Peter Röttgen, Claudia Büttner, Uwe Reusch
Abstract: Described is a combination of at least two antibodies, characterized by the following properties: (a) it comprises at least two different multivalent antibodies, each one having at least two specificities and being characterized by features (b) and (d) or (b) and (c) as defined below, (b) an antigen-binding domain specific to a tumor antigen, (c) an antigen-binding domain specific to an antigen present on human T cells, or (d) an antigen-binding domain specific to an antigen present on CD3-epsilon negative human effector cells. Also described are polynucleotides encoding said antibodies as well as vectors comprising said polynucleotides, host cells transformed therewith and their use in the production of said antibodies. Finally, compositions, preferably pharmaceutical and diagnostic compositions, are described comprising the above mentioned polynucleotides, antibodies or vectors.
Type:
Application
Filed:
February 23, 2008
Publication date:
June 19, 2008
Applicant:
AFFIMED THERAPEUTICS, AG
Inventors:
Sergey Kipriyanov, Fabrice Le Gall, Bjorn Cochlovius, Melvyn Little